KR20140043078A - 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 - Google Patents

알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Download PDF

Info

Publication number
KR20140043078A
KR20140043078A KR1020137031028A KR20137031028A KR20140043078A KR 20140043078 A KR20140043078 A KR 20140043078A KR 1020137031028 A KR1020137031028 A KR 1020137031028A KR 20137031028 A KR20137031028 A KR 20137031028A KR 20140043078 A KR20140043078 A KR 20140043078A
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
group
alkenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137031028A
Other languages
English (en)
Korean (ko)
Inventor
요셉 모스칼
Original Assignee
노오쓰웨스턴 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노오쓰웨스턴 유니버시티 filed Critical 노오쓰웨스턴 유니버시티
Publication of KR20140043078A publication Critical patent/KR20140043078A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137031028A 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Ceased KR20140043078A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US61/479,593 2011-04-27
US201161527744P 2011-08-26 2011-08-26
US61/527,744 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020187022910A Division KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020197008907A Division KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Publications (1)

Publication Number Publication Date
KR20140043078A true KR20140043078A (ko) 2014-04-08

Family

ID=47073094

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020137031028A Ceased KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020207011211A Ceased KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020217011613A Ceased KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020197008907A Ceased KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020207011211A Ceased KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020217011613A Ceased KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020197008907A Ceased KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Country Status (13)

Country Link
US (4) US20140107037A1 (cg-RX-API-DMAC10.html)
EP (2) EP3679931A3 (cg-RX-API-DMAC10.html)
JP (1) JP6035326B2 (cg-RX-API-DMAC10.html)
KR (5) KR20140043078A (cg-RX-API-DMAC10.html)
CN (2) CN103974712A (cg-RX-API-DMAC10.html)
AU (1) AU2012249397B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013027554A2 (cg-RX-API-DMAC10.html)
CA (1) CA2834286A1 (cg-RX-API-DMAC10.html)
EA (2) EA201790653A1 (cg-RX-API-DMAC10.html)
HK (1) HK1258231A1 (cg-RX-API-DMAC10.html)
MX (1) MX357761B (cg-RX-API-DMAC10.html)
SG (2) SG10202010665YA (cg-RX-API-DMAC10.html)
WO (1) WO2012149389A2 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
SG10201501050RA (en) 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201505937SA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP6419087B2 (ja) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US9745342B2 (en) 2013-10-28 2017-08-29 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
US20160345855A1 (en) * 2013-12-13 2016-12-01 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
RU2721401C2 (ru) * 2014-06-23 2020-05-19 Нортвестерн Юниверсити Способы лечения или облегчения мигрени
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033757A1 (en) * 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
ATE499104T1 (de) * 2005-03-24 2011-03-15 Univ Emory Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
WO2009105718A1 (en) * 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033757A1 (en) * 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases

Also Published As

Publication number Publication date
HK1258231A1 (zh) 2019-11-08
AU2012249397A1 (en) 2013-11-07
MX357761B (es) 2018-07-23
EA201790653A1 (ru) 2017-07-31
JP2014520072A (ja) 2014-08-21
JP6035326B2 (ja) 2016-11-30
US20170049845A1 (en) 2017-02-23
EA201391581A1 (ru) 2014-05-30
WO2012149389A2 (en) 2012-11-01
EP3679931A3 (en) 2020-10-14
SG194230A1 (en) 2013-12-30
MX2013012526A (es) 2014-04-16
CA2834286A1 (en) 2012-11-01
CN103974712A (zh) 2014-08-06
WO2012149389A3 (en) 2014-05-08
AU2012249397B2 (en) 2017-03-30
EA029999B1 (ru) 2018-06-29
US20190209642A1 (en) 2019-07-11
KR20200043534A (ko) 2020-04-27
US20140107037A1 (en) 2014-04-17
EP2701721A4 (en) 2015-12-16
SG10202010665YA (en) 2020-11-27
KR20210046843A (ko) 2021-04-28
KR20180095096A (ko) 2018-08-24
CN108283712A (zh) 2018-07-17
EP2701721A2 (en) 2014-03-05
BR112013027554A2 (pt) 2016-09-06
US20210169964A1 (en) 2021-06-10
EP3679931A2 (en) 2020-07-15
KR20190037359A (ko) 2019-04-05

Similar Documents

Publication Publication Date Title
US20210169964A1 (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
Herrando‐Grabulosa et al. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis
Bramham et al. The Arc of synaptic memory
He et al. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons
Picconi et al. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons
Ovsepian et al. Selective vulnerability of motor neuron types and functional groups to degeneration in amyotrophic lateral sclerosis: review of the neurobiological mechanisms and functional correlates
Stern et al. Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease
Pergolizzi et al. The sigma enigma: A narrative review of sigma receptors
White et al. Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models
Huang et al. Increase of insulin sensitivity and reversal of age-dependent glucose intolerance with inhibition of ASIC3
Shudo et al. A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm
Crook et al. Surveying the landscape of Huntington's disease mechanisms, measurements, and medicines
Cavalcante et al. GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders
HK40034037A (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
Nowaczyk et al. Docking and pharmacodynamic studies on hGAT1 inhibition activity in the presence of selected neuronal and astrocytic inhibitors. Part I
JPH10508579A (ja) シナプス伝達を改善する薬
Gardner et al. The neurobiology of nicotine addiction: Clinical and public policy implications
CN116407634B (zh) 增加Slack蛋白C端含量的物质的应用
Bonifacino et al. Alterations of Synaptic Mechanisms and Excessive Glutamate Release in the Spinal Cord of SOD1G93A Mice
Potey et al. N-Methyl-d-Aspartate Receptors Remain Viable Therapeutic Targets for Stroke
Dayre Sex-specific sociability deficits in the zQ175 mouse model of Huntington’s Disease
CA2968933C (en) Peptides for use in neurodegenerative disorders
Balbi Group I metabotropic glutamatergic receptors regulating glutamate release and microglia phenotype in a murine model of amyotrophic lateral sclerosis
Park et al. Knight in Splicing Armor: Alternative Splicing as a Neuroprotective Mechanism
WO2022200260A1 (de) Verwendung von l-enantiomeren peptidliganden von nativ gefalteter humaner superoxiddismutase 1 (sod1) für die therapie von amyotropher lateralsklerose (als)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170427

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180208

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180808

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180208

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190327